EQS Newswire / 13/02/2023 / 09:59 UTC+8 Suzhou, February 10, 2023 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. Phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound. […]
Tag: gt20029
Kintor Pharma announced completion of phase I trial of the world’s first PROTAC compound (GT20029) for topical use
EQS Newswire / 24/11/2022 / 09:48 UTC+8 Kintor Pharma announced completion of phase I trial of the world’s first PROTAC compound (GT20029) for topical use Suzhou, November 24, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the top-line results for its phase […]
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
EQS Newswire / 27/10/2022 / 17:58 UTC+8 Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US Suzhou, October 27, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company […]